Susan Tzotzos

Dr. Susan Tzotzos

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2020 in Critical Care
Verified
Journal Article
Open access
PDF file
STSusan Tzotzos
Susan Tzotzos
BFBernhard Fischer
Bernhard Fischer
HFHendrik Fischer
Hendrik Fischer
MZMarkus Zeitlinger
Markus Zeitlinger

Verified
Journal Article
Open access
PDF file
RLRosa Lemmens-Gruber
Rosa Lemmens-Gruber
STSusan Tzotzos
Susan Tzotzos
Epithelial sodium channels (ENaC) are part of a complex network of interacting biochemical pathways and as such are involved in several disease states. Dependent on site and type of mutation, gain- or loss-of-function generated symptoms occur which span from asymptomatic to life-threatening disorders such as Liddle syndrome, cystic fibrosis or generalized pseudohypoaldosteronism type 1. Variants of ENaC which are implicated in disease assist further understanding of their molecular mechanisms in order to create models for specific pharmacological targeting. Identification and characterization of ENaC modifiers not only furthers our basic understanding of how these regulatory processes interact, but also enables discovery of new therapeutic targets for the disease conditions caused by ENaC dysfunction. Numerous test compounds have revealed encouraging results in vitro and in animal models but less in clinical settings. The EMA- and FDA-designated orphan drug solnatide is currently being tested in phase 2 clinical trials in the setting of acute respiratory distress syndrome, and the NOX1/ NOX4 inhibitor setanaxib is undergoing clinical phase 2 and 3 trials for therapy of primary biliary cholangitis, liver stiffness, and carcinoma. The established ENaC blocker amiloride is mainly used as an add-on drug in the therapy of resistant hypertension and is being studied in ongoing clinical phase 3 and 4 trials for special applications. This review focuses on discussing some recent developments in the search for novel therapeutic agents.

1 June 2013 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
STSusan Tzotzos
Susan Tzotzos
BFBernhard Fischer
Bernhard Fischer
HFHendrik Fischer
Hendrik Fischer
HPHelmut Pietschmann
Helmut Pietschmann
RLRudolf Lucas
Rudolf Lucas
WSWaheed Shabbir
Waheed Shabbir

26 February 2022 in Journal of Peptide Science
Verified
Journal Article
Open access
PDF file
STSusan Tzotzos
Susan Tzotzos
Stapled peptides are synthetic peptidomimetics of bioactive sites in folded proteins which carry chemical links, introduced during peptide synthesis, designed to retain the secondary structure in the native protein molecule. Stapled peptides have been investigated as potential modulators of protein–protein interactions for over two decades. The potential use of stapled peptides as inhibitors of viral entry, and therefore as antiviral therapeutics, has been established for several important viruses causing disease in humans, such as the human immunodeficiency virus type 1 (HIV‐1), respiratory syncytial virus (RSV), and Middle East Respiratory Syndrome (MERS) coronavirus. Several independent research initiatives have investigated the inhibitory effect of stapled peptides on binding of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of COVID‐19, to its receptor, angiotensin‐converting‐enzyme 2 (ACE2). These stapled peptides, which mimic Helix 1 of the human ACE2 receptor, have demonstrated mixed ability to prevent infection with SARS‐CoV‐2 in cell‐based studies.

27 April 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
PMPau Martin-Malpartida
Pau Martin-Malpartida
SASilvia Arrastia-Casado
Silvia Arrastia-Casado
JFJosep Farrera-Sinfreu
Josep Farrera-Sinfreu
RLRudolf Lucas
Rudolf Lucas
HFHendrik Fischer
Hendrik Fischer
Maria J. MaciasMaria J. Macias
Maria J. Macias
• Solnatide is a 17-mer cyclic peptide. • The cyclic peptide mimics the sequence and function of the lectin-like domain of human TNF. • Solnatide enhances alveolar fluid clearance in various preclinical and recent clinical studies. • Solnatide folds as an ensemble of conformations that share a small hydrophobic core and two electrostatically charged poles. • Using RosettaDock, we model how the peptide and the C-terminal region of the ENaCα subunit might interact in cells.